Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting
April 03, 2019 07:05 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics Announces Clinical Programs Update
April 03, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
- Design of cervical cancer study amended in anticipation for regulatory interactions - - Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung...
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
April 02, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
- Patient dosing commenced in pivotal metastatic melanoma cohort - - Submission for regulatory approval of lifileucel is on target for late 2020 - SAN CARLOS, Calif., April 02, 2019 (GLOBE...
Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
April 01, 2019 08:00 ET
|
Iovance Biotherapeutics, Inc.
- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma - SAN CARLOS, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics,...
Iovance Biotherapeutics Announces April Scientific and Investor Presentations
March 29, 2019 08:23 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
March 06, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
February 27, 2019 16:01 ET
|
Iovance Biotherapeutics, Inc.
- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent,...
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
February 22, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
February 01, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 21, 2018 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...